PLasmatic Extracellular Vesicles AS Biomarkers of nEural Tissue Damage

Sponsor
Roberto Furlan
Study ID
NCT07769294
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

Recently proposed central nervous system damage biomarkers detectable in biofluids, such as neurofilament light chain (NfL) have several limits, including a lack in specificity and a kinetic that does not allow them to be used as outcome measures in clinical trials for neurodegenerative diseases such as the progressive forms of multiple sclerosis (MS) or the sequelae of stroke. Our team has pioneered the detection of central nervous system (CNS) extracellular vesicles (EVs) as biomarkers in MS and Alzheimer's Disease. If EVs are not the best solution themselves, we propose also to investigate their content to reveal potential new biomarkers having the same significance and an easier detection technology. Thus, we propose here to set-up front line technologies to detect EVs of CNS origin, or their content, in the plasma of persons affected by MS or by stroke to find better ways to monitor ongoing neurodegenerative processes and therefore allow easier development of new treatments.

Key Dates

First listed
Aug 17, 2026
Start date
Sep 15, 2026
Status verified
Aug 2026
Primary completion
Mar 31, 2028
Completion
Jul 31, 2028

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Multiple Sclerosis
    Persons with multiple sclerosis undergoing diagnostic workup
  • Arm: Stroke
    Persons admitted to the Stroke Unit for ischemic stroke
  • Arm: Healthy Donors
    Healthy donors matched for age and sex

Primary Outcome Measure

Neural plasma extracellular vesicles [ Time Frame: Baseline, 3months, 6months, 12 months for multiple sclerosis. Baseline, and 1, 7 and 14 days after stroke for stroke patients. Once for healthy donors. ]

Central Contacts

Find similar trials

Nationwide
Multiple sclerosis trialsStroke trialsNeurology trialsBrain disorders trialsAutoimmune disease trials

Related Studies